Michele Milella, Director of Department of Engineering for Innovation Medicine (DIMI) at The University of Verona, shared a post on LinkedIn:
“I’m delighted to share our recently published data on “Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants”, a huge collaborative effort from the Italian oncological community!
While heterogeneity of response to PARPi (an platinum derivatives…) in pancreatic cancer requires more effective biomarkers than just gBRCA1/2 mutational status, I believe we all agree that olaparib can profoundly alter disease trajectory in individual pancreatic cancer patients who carry a gBRCA1/2 mutation…
Here are real-world data supporting such conclusion, strongly calling (in my opinion) for devising ways to allow drug access for these patients!
A sincere thank you to all the colleagues, friends, and patients who contributed to this important piece of work!
Stay tuned for more research on this topic!”
Authors: Michele Milella et al.
